Latest news with #AMF
Wall Street Journal
2 days ago
- Business
- Wall Street Journal
Shares in Vivendi Rise After French Regulator Mandates Buyout Offer From Bollore
Shares in Vivendi VIV 12.47%increase; green up pointing triangle climbed on news that France's market regulator required the company's main shareholders, Vincent Bollore and the namesake firm his family controls, to bid for full ownership after minority stockholders challenged in court Vivendi's breakup last year. The French regulator, known as AMF, required the Bollore Group BOL -0.37%decrease; red down pointing triangle and Vincent Bollore to file the offer within a time limit of six months.
News.com.au
6 days ago
- Business
- News.com.au
Moorabbin bowling alley saved as General Public reveals plans
Melbourne's longest running bowling alley is set to be reopened in time for Christmas after a more than $10m play that has saved it from developers. The Moorabbin bowling lanes date back to the 1964, and have been operated by popular groups from AMF to Zone. It's now just months away from being reopened under the banner of General Public, who plan to not only reopen it — but make it a bigger draw card for families from as far as Melbourne's Bayside suburbs. Inside East Sunbury's new $80m shopping village Actor Ryan Reynolds, Wrexham help pay Aussie mortgages General Public managing director Harry Kourbeis said while they were still firming up all of their plans, the bowling lanes would definitely be a part of it — but there will be less of them. 'You can expected another bowling offering to come back to what is known as one of the earliest bowling centres in Victoria,' Mr Kourbeis said. 'And we're hoping to open by early December. 'But we will reduce the lanes to 12. We are expecting more of a social interest, than a competitive bowling one, so that will give more room for other activities.' General Public also have venues in Dingley, Frankston, Corio in Geelong and the Queensland city of Ipswich. They typically offer bowling, gaming arcades, pool tables, and golfing simulators. Bowling leagues, as well as kids events are among their regular offerings. They're also planning to give the venue a menu makeover and offer 'good comfort food' made from quality ingredients that suits casual dining – and takes things a step beyond the usual bowling alley fare. Mr Kourbeis said when he had seen the forthcoming sale sign at the property while driving to one of the existing General Public sites in Dingley he 'couldn't stop quickly enough to get the details'. 'I thought it was perfectly located,' he said. The entertainment retail industry veteran also appreciated the site's 1960s character, something he has little intention of changing on the outside — despite bigger plans for inside. The local landmark at 944-954 Nepean Highway was listed for sale in January and sold in March this year for $10.2m. Three months later, Zone Bowling in Moorabbin was closed on June 13 ahead of a new site under that brand being opened at Southland on June 19. JLL's Dominic McGrath worked on the sale and said there had been interest from retailers as well as developers, despite heritage aspects giving some pause to those planning a significant transformation. 'But a lot of retailers and some developers were looking at it,' Mr McGrath said. 'The size gave it a lot of flexibility, so it was a competitive campaign.' He added that with other parties still looking, there was still demand in the $10m range for larger Moorabbin addresses. However, Mr McGrath said it was a good thing for Melbourne that a bowling alley was likely to continue on at the site. 'A lot of people we spoke to knew it straight away, having taken their kids there and having gone there when they were younger,' he said. 'So it's great for the area that it may stay there. People in the bayside area will be pretty rapt to see it continue as a bowling alley.' JLL's Xander Yeo was also involved in the sale and said it was a win for the wider community that the 'Nepean Highway landmark' would continue on as an entertainment spot.
Business Wire
11-07-2025
- Business
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of June 30 th, 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French 'Code de Commerce' and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or 'AMF'), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of June 30 th, 2025. * 192,300 free shares have been issued during the month in accordance with the plans detailed in section 5.1.5.2 of the 2024 Universal Registration Document, released on April 29, 2025. (1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. (2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is provided for the information of the public, in accordance with the AMF recommendation of July 17, 2007. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Yahoo
08-07-2025
- Business
- Yahoo
AB Science announces the successful completion of a EUR 1.925 million private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.925 MILLION PRIVATE PLACEMENT Paris, July 8, 2025, 8am AB Science S.A. (the 'Company' or 'AB Science', Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors (the 'Private Placement'). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the 'AMF'). In accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the 'Prospectus Regulation'), the Company file with the AMF a document containing the information set out in Appendix IX of the Prospectus Regulation (the 'Information document'), copies of which will be available free of charge on the Company's website at and on the AMF's website at Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. This transaction strengthens the Company's cash position and enables it to cover its financing needs in 2025 and beyond the next 12 months, taking into account the explanations set out in section 5.2.1.5 (note 2) of the 2024 financial report. Terms and conditions of the Private Placement The Private Placement, for a total amount of EUR 1.925 million (including share issue premium), was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of 1,645,302 new ordinary shares in the Company (the 'New Shares'), each with one share warrant attached (a 'BSA' and, together with the New Share to which it is attached, an 'ABSA'), as part of a share capital increase with cancellation of shareholders' preferential subscription rights for the benefit of investors within the category of persons defined by the 16th resolution of the Combined General Meeting of the Company's shareholders of June 30, 2025 (the 'General Meeting'), in accordance with Article L. 225-138 of the French commercial code (the 'Private Placement'). The issue of the ABSAs, representing approximately 2.47% of the Company's share capital, on a non-diluted basis, before completion of the Private Placement, and 2,41% of the Company's share capital, on a non-diluted basis, after completion of the Private Placement, was decided on July 7, 2025 by the Chief Executive Officer, pursuant to the delegation of competence granted to him by the board of directors dated July 7, 2025, pursuant to the delegation of competence granted to it under the 16th resolution of the General Meeting . The issue price of one ABSA is EUR 1.17 (including share issue premium), representing a facial discount of 24.36% (i.e. EUR 0.38) to the volume-weighted average price of the AB Science shares on the regulated market of Euronext Paris ('Euronext Paris') over the three trading days preceding the setting of such issue price, i.e. July 7, 4 and 3, 2025 (the '3-day VWAP'). The issue price of an ABSA, including the theoretical value of the BSA attached to it (as described below, together with the exercise price of such BSA) represents a total 18.84% discount per AB Science share to the 3-day VWAP, consistent with the maximum discount authorized by the General Meeting pursuant to its 16th resolution. Terms and conditions of the BSA One BSA is attached to each New Share. One BSA entitles their holder to subscribe to one new ordinary share of the Company, at a price of EUR 1.78 per ordinary share. The BSAs may be exercised at any time within 60 months of their issuance. In the event all BSAs are exercised, a total number of 1,645,302 additional ordinary shares of the Company will be issued, representing additional total proceeds of approximately EUR 2.93 million. The theoretical value of each BSA, assuming a volatility of 34.355%1 and based on closing price as of July 7, 2025, is equal to EUR 0.4392 using Black & Scholes model. The BSAs will be immediately detached (détachés) from the New Shares upon issuance and are expected to be listed on Euronext Growth Paris ('Euronext Growth Paris') on or prior to July 14, 2025. Impact of the Private Placement on the Company's shareholding Following the issuance of the ABSAs, the Company's total share capital will be EUR 681,937.55 (or EUR 698,390.57 in the event of exercise of all BSAs). It will be comprised of 61,431,076 ordinary shares (or of 63,076,378 ordinary shares in the event of exercise of all BSAs) with a par value of EUR 0.01. There will be no change on the number of preferred shares. On the basis of the share capital of the Company immediately after completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company's share capital prior to the above-mentioned capital increase and who did not subscribe to it now stands at 0.98% on a non-diluted basis and 0.79% on a diluted basis. Admission to trading of the New Shares The New Shares are expected to be admitted to trading on the regulated market of Euronext Paris on July 10, 2025. The New Shares will be subject to the provisions of the Company's by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0010557264 – AB. Lock-up commitments The Company has signed a lock-up commitment (to the benefit of the investors) pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. The directors and officers of the Company have signed a lock-up commitment pursuant to which they have agreed to a lock-up period of 90 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. Indicative timetable July 7, 2025 Decisions of the Board of Directors deciding the principle of the Private Placement. July 7, 2025 Decisions of the Chief Executive Officer setting the terms and conditions of the Private Placement (including the subscription price of the ABSAs and the gross amount of the Private Placement). July 8, 2025 Publication of this press of the Information Document. July 10, 2025 Publication of the Euronext notice of admission of the New Shares to trading on Euronext Paris. July 10, 2025 Settlement-delivery of the ABSAs - Detachment of the BSA - Start of trading of the New Shares on Euronext Paris. July 14, 2025 Admission of the BSAs on Euronext Growth Paris. Risk factors AB Science draws the attention of the public to the risk factors relating to the Company and its business described in its annual management reports and press releases, which are available free of charge on the Company's website ( In addition, the main risks specific to securities are as follows: The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of AB Science diluted, and this shareholding may also be diluted in the event of exercise of the BSA, as well as in the event of new securities transactions. The volatility and liquidity of AB Science shares could fluctuate significantly. The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price. About masitinib Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique mode of action, the Company believed that masitinib can be developed in a wide range of diseases, including oncology, inflammatory diseases, and certain central nervous system diseases. In oncology, through its immunotherapy activity, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases. About AB8939 AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Disclaimer This press release and the information contained herein do not constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for the New Shares in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration under the U.S. Securities Act or an exemption from registration under the U.S. Securities Act. AB Science does not intend to make a public offering of the New Shares in the United States of America or in any other jurisdiction. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on the current expectations and beliefs of AB Science's management and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. AB Science and its affiliates, directors, officers, employees, consultants or agents do not undertake, and are not under any obligation, to release any updates to any forward-looking statement or to revise any forward-looking statement. For additional information, please contact: AB Science Financial communication and public relationsinvestors@ 1Based on the volatility overt the last 12 months of the Euronext Next Biotech index. Attachment AB Science - AK July 2025 Press Release VEng VFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-07-2025
- Business
- Yahoo
Alstom S.A.: Half-year liquidity contract statement for Alstom
PRESS RELEASE 7 July 2025 – Under the liquidity contract entrusted by Alstom to Rothschild Martin Maurel, as of June 30, 2025, the following resources appeared in the liquidity account: 0 security €17 987 200 Over the period from 2025/01/01 to 2025/06/30, the number of transactions processed is as follows: Number of transactions carried out Number of securities traded Amount of transactions (in €) Buy 19 563 7 262 678 149 362 897.45 Sell 22 488 7 262 678 149 345 792.22 As of 31st of December 2024, the following resources appeared in the liquidity account: 0 security € 18 004 305 The implementation of this report is carried out in accordance with AMF decision n°2021-01 of June 22, 2021 renewing the introduction of liquidity contracts on equity securities as an accepted market practice. The complete transaction template is available in the attached PDF document. ALSTOM™ is a protected trademark of the Alstom Group. About Alstom Alstom commits to contribute to a low carbon future by developing and promoting innovative and sustainable transportation solutions that people enjoy riding. From high-speed trains, metros, monorails, trams, to turnkey systems, services, infrastructure, signalling and digital mobility, Alstom offers its diverse customers the broadest portfolio in the industry. With its presence in 63 countries and a talent base of over 86,000 people from 184 nationalities, the company focuses its design, innovation, and project management skills to where mobility solutions are needed most. Listed in France, Alstom generated sales of €18.5 billion for the fiscal year ending on 31 March 2025. For more information, please visit Contacts PressPhilippe MOLITOR - Tel. : +33 (0) 7 76 00 97 79 Thomas ANTOINE - Tel. : +33 (0) 6 11 47 28 Investor RelationsCyril GUERIN - Tel.: +33 (0)6 07 89 36 Guillaume GAUVILLE - Tel: +44 (0)7 588 022 Estelle MATURELL ANDINO - Tel: +33 (0)6 71 37 47 56 Jalal DAHMANE - Tel: +33 (0)6 98 19 96 Attachment 20250707_PR_Contract_Liquidity_S_12025_EN
